FDA approves change to drug label after reports of gastrointestinal problems and weight loss.
The U.S. Food and Drug Administration (FDA) released a safety announcement earlier this week warning healthcare providers and consumers about the potential side effects of olmesartan medoxomil, a blood pressure medication that goes by the brand names Benicar, Benicar HCT, Azor, Tribenzor and is also found in generics. According to the FDA, the medication can cause severe chronic diarrhea and weight loss – symptoms often associated with celiac disease. The medication label will now include a warning about this potential reaction.
Celiac disease expert and NFCA Scientific/Medical Advisory Council Member Dr. Joseph Murray of the Mayo Clinic recognized the reaction and reported his concerns in a press release and video published in June 2012. At the time, he encouraged other medical providers to contact the FDA if they identify similar cases. He also advised patients to talk to their doctor if they are experiencing celiac disease-like symptoms while taking olmesartan medoxomil.
For more information, read the FDA’s safety announcement.